A comprehensive analysis identified an autophagy-related risk model for predicting recurrence and immunotherapy response in stage I lung adenocarcinoma
PeerJ · 2025
DOI: 10.7717/peerj.19366 ↗Kurz gefasst
Fachartikel in der Zeitschrift PeerJ, 2025. Verfasst von Hongmei Zheng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The Second Xiangya Hospital, Central South University, Changsha, China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Autophagy, Lung Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Hunan Province.
Abstract (Originalsprache)
Background
Lung adenocarcinoma (LUAD) is characterized by early recurrence and poor prognosis. Autophagy is a double-edged sword in tumor development and anti-tumor therapy resistance. However, the prediction of relapse and therapeutic response in LUAD patients with stage I based on the signature of autophagy remains unclear.
Methods
Gene expression data were obtained from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) database. Autophagy-associated genes were extracted from the Human Autophagy Moderator Database. The autophagy score was established by Least Absolute Shrinkage and Selection Operator (LASSO) regression. Real-time PCR was used to detect gene expression of hub genes in LUAD patients. Protein-protein interaction (PPI) was analyzed to identify crucial genes. Gene set enrichment analysis (GSEA) was used to reveal the molecular features of patients. ESTIMATE algorithm was applied to estimate the tumor immune infiltration. TIDE score and Genomics of Drug Sensitivity in Cancer (GDSC) database were used to assess therapeutic response.
Results
We established an autophagy score based on 19 autophagy genes. Among these genes, MAP1LC3B played a crucial role in PPI network and was down-regulated in tumor tissues both in TCGA and local cohort. Receiver operating characteristic (ROC) curve showed that the risk model effectively predict RFS of stage I LUAD (area under the curve (AUC) at 1, 2, 3 years = 0.701, 0.836, and 0.818, respectively). Multivariate regression analysis indicated that the autophagy score was an independent predictor for relapse ( P < 0.001, HR = 4.8, 95% CI [3.25–7.2]). The autophagy score also showed great predictive efficacy in the external validation GEO cohorts. GSEA revealed gene sets significantly enriched in immunity, cell cycle, and adhesion, etc . Meanwhile, we found the autophagy score was negatively related to KRAS mutation ( P = 0.017) but positively associated with TP53 mutation ( P = 6.4e−11). The autophagy score had a negative relationship with CD8+, CD4+ T cell, and dendritic cell, and positively correlated with immune checkpoint molecule CD276. Patients with a high autophagy score were sensitive to chemotherapy and targeted therapy, while resistant to immune checkpoint inhibitors.
Conclusion
We constructed an effective recurrence risk predictive model for stage I LUAD patients based on autophagy related genes. High autophagy score predicted a higher recurrence risk and suppressing tumor immune microenvironment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, The Second Xiangya Hospital, Central South University, Changsha, China.
- Hunan Clinical Medical Research Center for Cancer Pathogenic Genes Testing and Diagnosis, Changsha, Hunan, China.
- Department of Oncology, Xiangya Hospital, Central South University, Changsha, China.
- Department of Pathology, Xiangya Hospital, Central South University, Changsha, China.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Hunan Province
Zitieren
APA
Zheng, H., Fan, S., Zang, H., Luo, J., Shu, L., & Peng, J. (2025). A comprehensive analysis identified an autophagy-related risk model for predicting recurrence and immunotherapy response in stage I lung adenocarcinoma. PeerJ. https://doi.org/10.7717/peerj.19366
Vancouver
Zheng H, Fan S, Zang H, Luo J, Shu L, Peng J. A comprehensive analysis identified an autophagy-related risk model for predicting recurrence and immunotherapy response in stage I lung adenocarcinoma. PeerJ. 2025. doi:10.7717/peerj.19366
BibTeX
@article{Zheng2025,
author = {Zheng, Hongmei and Fan, Songqing and Zang, Hongjing and Luo, Jiadi and Shu, Long and Peng, Jinwu},
title = {A comprehensive analysis identified an autophagy-related risk model for predicting recurrence and immunotherapy response in stage I lung adenocarcinoma},
journal = {PeerJ},
year = {2025},
doi = {10.7717/peerj.19366}
}
EUVIMED